Abstract
With the topical focus on the prevention of and countermeasures for frailty, scattered studies have subdivided its social elements and aspects as "social frailty." While the concepts and definition of "social frailty" are yet to be established, the purpose of using the term is to capture the attention of professionals using the social aspects of frailty to support older adults. The goal is to increase healthy life expectancy by recognizing that social factors are unlikely to pose a risk of functional decline in isolation, but may increase such a decline when combined with other factors. At feasible scopes of intervention, ways to address these factors should be pursued. Although social aspects are often expressed by frail people, or social factors with complex processes that can cause functional decline, there is no unified definition or indicator of social frailty. Further research and discussion are needed to clarify its academic significance and usefulness for disability prevention. Recognizing this, when the Japanese Socio-Gerontological Society's Study Committee on "Social Frailty" published its recommendations, it suggested that when using the term "social frailty" we should specify the significance of its use; consider the comprehensiveness of frailty; be mindful of the interrelationship of social activities and other social aspects; and consider environmental conditions such as a person's values, preferences and life course, social norms, systems, and government policies. High-risk individuals may need multidisciplinary approaches delivered by various professionals, including clinicians, in realizing a life in line with their unique values and preferences. In such cases, it is necessary to understand the background and process that led to frailty, from physical, psychological, and social perspectives, referring to the abovementioned four points. The introduction of social aspects as one of the assessment frameworks can significantly bridge the gap between medical care and the community. Geriatr Gerontol Int 2022; 22: 991-996.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.